07.09.2022 Views

Lishan Su, PhD Investiture Program

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

LISHAN SU, PHD<br />

of North Carolina-Chapel Hill.<br />

<strong>Lishan</strong> <strong>Su</strong>, <strong>PhD</strong> grew up in Qingdao,<br />

China, and received his BS in Microbiology<br />

from Shandong University, <strong>PhD</strong> in Virology<br />

from Harvard University, and did postdoctoral<br />

training in Immunology at Stanford<br />

University. Dr. <strong>Su</strong> then worked as a<br />

research scientist in a biotech company,<br />

focusing on HIV pathogenesis and testing<br />

blood stem cell-based HIV-1 gene therapy<br />

in HIV-infected patients. From 1996 to<br />

2021, he was a faculty member in the<br />

Lineberger Comprehensive Cancer Center<br />

and Professor in the Department of<br />

Microbiology & Immunology at University<br />

For over two decades, Dr. <strong>Su</strong> has focused on studying several critical areas<br />

of immuno-pathology of human chronic virus infections, particularly on<br />

elucidating how HIV causes AIDS-related diseases. The <strong>Su</strong> laboratory<br />

studies how HIV-1 and HBV interact with human immune cells to cause<br />

diseases. His research team has focused on the plasmacytoid dendritic cell<br />

(pDC)-interferon axis in the pathogenesis and therapy of chronic HIV<br />

infection and Disease-Associated Macrophages (DAM)-hepatic stellate cells<br />

in HBV-induced liver diseases in humanized mice and in patients. The team<br />

has also started investigation of the pathways in tumor microenvironments<br />

(TME) and in cancer immune therapy. After joining The Institute of Human<br />

Virology at UMSOM, Dr. <strong>Su</strong> continued his research program to use HIV and<br />

HBV viruses as probes to dissect human immunity and inflammatory<br />

diseases, and to develop antibody and cell-based drugs targeting novel<br />

immune cells and signaling pathways to treat human inflammatory diseases<br />

including virus infection and cancer. He has also trained over 40 postdoc/<br />

visiting scholars and 20 graduate students from 8 different countries.<br />

Dr. <strong>Su</strong> has served on grant review committees for US/European and Chinese<br />

funding agencies for over 20 years, and as associate editor or on editorial<br />

boards of several journals. For the past 20 years, Dr. <strong>Su</strong> has also interacted<br />

with US and international institutions, including providing advice and to<br />

evaluate progress to biomedical research institutes and centers. He has also<br />

received several awards over the years, including election as a Fellow of the<br />

American Association for the Advancement of Science in 2012, and the<br />

Charles Gordon Smith Endowed Professorship for HIV Research in 2021.


WELCOME<br />

Mary Pooton<br />

Associate Dean for Development<br />

University of Maryland School of Medicine<br />

Margaret M. McCarthy, <strong>PhD</strong><br />

The James and Carolyn Frenkil Dean’s Professor and Chair,<br />

Department of Pharmacology<br />

Director, <strong>Program</strong> in Neuroscience<br />

University of Maryland School of Medicine<br />

REMARKS<br />

Mark T. Gladwin, MD<br />

Vice President for Medical Affairs, UM Baltimore<br />

John Z. and Akiko K. Bowers Distinguished Professor and<br />

Dean, University of Maryland School of Medicine<br />

DONOR RECOGNITION<br />

Mark T. Gladwin, MD<br />

SPEAKERS<br />

Robert C. Gallo, MD<br />

The Homer and Martha Gudelsky Distinguished Professor of Medicine<br />

Co-Founder & Director, Institute of Human Virology (IHV)<br />

University of Maryland School of Medicine<br />

Mike McCune, MD, <strong>PhD</strong><br />

Head, HIV Frontiers Initiatives<br />

Bill & Melinda Gates Foundation<br />

Yang Liu, <strong>PhD</strong><br />

Chief Executive Officer & Chief Scientific Officer<br />

OncoC4 Inc.<br />

Mark Bonyhadi, <strong>PhD</strong><br />

Senior Advisor<br />

Qiming Venture Partners USA<br />

MEDAL PRESENTATION<br />

Mark T. Gladwin, MD<br />

REMARKS<br />

<strong>Lishan</strong> <strong>Su</strong>, <strong>PhD</strong><br />

The Charles Gordon Smith Professor for HIV Research<br />

CLOSING REMARKS<br />

Margaret M. McCarthy, <strong>PhD</strong>


T<br />

he first endowed professorships were established more than<br />

500 years ago with the creation of the Lady Margaret chairs<br />

in divinity at Oxford and Cambridge Universities. The<br />

original endowed chairs were sponsored by Lady Margaret,<br />

countess of Richmond, and grandmother of Henry VIII in 1502.<br />

<strong>Su</strong>bsequently, private individuals began making financial contributions<br />

to establish other endowed professorships and chairs such as the<br />

Lucasian Chair of Mathematics, which Sir Isaac Newton held beginning<br />

in 1669. Professor Stephen Hawking, the internationally renowned<br />

physicist and recipient of the 2010 US Medal of Freedom, was another<br />

prominent holder of this endowed chair.<br />

The honor associated with appointment to an endowed position has<br />

remained unchanged for the last 500 years and is recognized as one of<br />

the highest tributes that an academic institution can bestow upon its<br />

most distinguished faculty. These endowed professorships and chairs<br />

continue to reward exceptional scholars uninterrupted to the present<br />

time.<br />

The Office of Development is charged with securing private gifts to<br />

ensure the School’s tradition of excellence is sustained through robust<br />

research, clinical, and educational programs and initiatives. The<br />

University of Maryland School of Medicine is fortunate to have nearly<br />

85 endowed chairs & professorships in various stages of completion<br />

and held by esteemed faculty members.


CHARLES GORDON SMITH<br />

Charles Gordon Smith of Fort Lauderdale, FL, cemented his own legacy<br />

in the advancement of virological research for years to come, with an<br />

endowed professorship at the University of Maryland School of Medicine’s<br />

(UMSOM) Institute of Human Virology (IHV) that now bears his name.<br />

His bequest, partially matched by Maryland E-Nnovation Initiative Fund<br />

(MEIF), created the Charles Gordon Smith Endowed Professorship for HIV<br />

Research.<br />

Smith’s posthumous gift was inspired by a June 2001 appearance on CNN<br />

by IHV director and co-founder Robert C. Gallo, MD, the Homer and<br />

Martha Gudelsky Distinguished Professor in Medicine and co-founder and<br />

director of IHV, which highlighted Gallo’s work to detect and treat HIV,<br />

the virus that causes AIDS. The interview sparked Mr. Smith’s growing<br />

interest in Dr. Gallo’s work and eventually, his desire to fund HIV research<br />

through his bequest.<br />

Mr. Smith was a staff accountant at Price Waterhouse and was described by<br />

friends as very scholarly with multiple degrees, an avid reader, and book<br />

collector with multiple interests who researched everything.<br />

“Charlie was a philanthropist and wanted to help so many,” noted a close<br />

friend of Mr. Smith, who requested anonymity. “Dr. Gallo had made an<br />

impact for Charlie, as much as Charlie is now making an impact for Dr.<br />

Gallo.”<br />

The E-Nnovation program was created as an economic stimulus in 2014, as<br />

a special non-lapsing fund designed to help the state’s research universities<br />

recruit and retain top scientists and investigators. Administered by the<br />

Maryland Department of Commerce, MEIF funds combined with private<br />

philanthropy from Mr. Smith’s estate, has allowed the creation of this new<br />

endowed professorship.<br />

UMSOM is very thankful for this bequest from Mr. Smith that has allowed<br />

us to appoint the inaugural Charles Gordon Smith Endowed Professor of<br />

HIV Research.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!